In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
The UK’s health technology assessor has approved the first chimeric antigen receptor (CAR) T-cell therapy for use on the National Health Service (NHS) in England. 26 January 2023
Biotechnology
KSQ Therapeutics, a privately-held US biotech developing therapies to treat cancer and autoimmune diseases using its CRISPRomics platform, has announced a deal with Ono Pharmaceutical. 25 January 2023
Pharmaceutical
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee has voted favorably, by 14 to 1, that Cidara Therapeutics, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin. 25 January 2023
Pharmaceutical
US drugmaker Eli Lilly is to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company's Research Triangle Park facility in North Carolina. 25 January 2023
Biotechnology
Histiocytic neoplasms, also known as histiocytosis, are rare disorders in which specialized immune cells (histiocytes) accumulate and form tumors in tissues such as skin, bones, liver, lungs, lymph nodes and spleen.1,2 25 January 2023
Pharmaceutical
The Chinese Center for Disease Control and Prevention has recorded that Omicron lineages BA.5.2 and BF.7 account for 97.5% of all local infections in the country. 25 January 2023
Biotechnology
The European Medicines Agency is to review a regulatory submission from Swiss gene editing specialist CRISPR Therapeutics and partner Vertex Pharmaceutical. 25 January 2023
Pharmaceutical
The US Department of Health and Human Services (HHS) yesterday issued a new report showing the major savings coming to people with Medicare thanks to the $35 cap on a month’s supply of insulin. 25 January 2023
Biotechnology
Deciphera Pharmaceuticals’ shares rose 4.4% to $18.85 in after-hours trading yesterday, when the US biopharma company presented additional data from the planned exploratory analysis from the INTRIGUE Phase III clinical study of Qinlock (ripretinib) using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. 25 January 2023
Biotechnology
More gloomy news from Finch Therapeutics, as the microbiome company announced it would scrap the Phase III PRISM4 trial of its recurrent C. difficile infection (CDI) candidate CP101. 25 January 2023
Generics
US tech giant Amazon has announced RxPass, a new Prime membership benefit from Amazon Pharmacy that offers patients affordable access to commonly prescribed generic medications that treat more than 80 common health conditions. 25 January 2023
Pharmaceutical
Revenues in the fourth quarter came in below expectations for Johnson & Johnson, with the company reporting sales of $23.7 billion, a decline of 4.4%. 24 January 2023
Pharmaceutical
A new chief executive is to take over from Jeff Hatfield at Vividion Therapeutics, Bayer’s wholly-owned subsidiary that is using discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. 24 January 2023
Pharmaceutical
The European Commission Decision Reliance Procedure (ECDRP) has been extended to December 31, 2023, when a new international recognition framework will be in place, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) announced today. 24 January 2023
Biotechnology
Boston, USA-based biotech Blueprint Medicines Corporation has announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental new drug application (sNDA) for Ayvakit (avapritinib) to treat indolent systemic mastocytosis (SM). 24 January 2023
Biotechnology
French therapeutic peptides for rare endocrine and metabolic diseases company Amolyt Pharma today announced it has entered into a research agreement and licensing option with XOMA Corp. 24 January 2023
Generics
Sandoz, the generic and biosimilar medicines business of Swiss pharma giant Novartis, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas Pharma. 24 January 2023
Biotechnology
Pliant Therapeutics, a Californian biopharma focused on discovering and developing fibrosis drugs, closed up by more than a third on Monday. 24 January 2023
Pharmaceutical
In a sudden turn of events, Novartis' Entresto (sacubitril/valsartan) patent has been reinstated in India, after a two-judge bench stayed a previous order that invalidated it. 24 January 2023
Pharmaceutical
Shares of US clinical-stage biotech Axcella Therapeutics were up nearly 70% at $0.72 pre-market this morning, after it announced a regulatory path to registration of AXA1125 in the treatment of long COVID fatigue. 24 January 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze